(2017). Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: A randomised, double-blind trial.
Chicago Style (17th ed.) CitationFinal Efficacy, Immunogenicity, and Safety Analyses of a Nine-valent Human Papillomavirus Vaccine in Women Aged 16–26 Years: A Randomised, Double-blind Trial. 2017.
MLA (8th ed.) CitationFinal Efficacy, Immunogenicity, and Safety Analyses of a Nine-valent Human Papillomavirus Vaccine in Women Aged 16–26 Years: A Randomised, Double-blind Trial. 2017.
Warning: These citations may not always be 100% accurate.